ArticleIntractable & rare diseases research2024

Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China.

Yashuang Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.